ONCODES.PREC.MED. EO-34 (ZR8) — Tangible Net Worth Ratio
ONCODES.PREC.MED. EO-34 (ZR8) has a Tangible Net Worth Ratio of 68.9% as of December 2023. This metric is calculated by deducting intangible assets (€1.15 Million) from net assets (€3.69 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore ONCODES.PREC.MED. EO-34 (ZR8) net asset momentum to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ONCODES.PREC.MED. EO-34 Tangible Net Worth Ratio (2021–2023)
This chart shows how ONCODES.PREC.MED. EO-34's Tangible Net Worth Ratio has changed across 3 annual periods from 2021 to 2023. As of December 2023, the ratio stands at 68.9%, reflecting net assets of €3.69 Million with intangible assets of €1.15 Million EUR. For live market cap and overall valuation, see ONCODES.PREC.MED. EO-34 (ZR8) total market value.
Annual Tangible Net Worth Ratio for ONCODES.PREC.MED. EO-34 (2021–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2023, covering 3 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 68.9% | €3.69 Million | €1.15 Million | €16.63 Million | ▼ -24.3 pp |
| 2022 | 93.3% | €11.78 Million | €794.47K | €18.37 Million | ▲ +8.0 pp |
| 2021 | 85.3% | €4.20 Million | €619.37K | €8.37 Million | — |